Patents Assigned to ALTIMMUNE INC
-
Patent number: 11541028Abstract: The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.Type: GrantFiled: January 3, 2019Date of Patent: January 3, 2023Assignee: Altimmune Inc.Inventor: John J Nestor
-
Publication number: 20220354943Abstract: Disclosed herein are methods for generating a protective immunogenic response via intranasal administration of an immunogenic composition (e.g., vaccine)/therapeutic immunogenic composition in a mammalian subject. Certain dosing positions of the subject during the administration of immunogenic agents, such that nostrils are tilted upwards, while in a modified sitting, reclining and/or supine posture, is surprisingly correlated with the generation of a strong immunogenic response in both humans and animals.Type: ApplicationFiled: August 13, 2020Publication date: November 10, 2022Applicant: Altimmune, IncInventors: Vyjayanthi Krishnan, M. Scot Roberts
-
Patent number: 11395802Abstract: Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided.Type: GrantFiled: September 15, 2017Date of Patent: July 26, 2022Assignees: Auburn University, Altimmune, Inc.Inventors: Allan E. David, Henry J. Baker, Aime K. Johnson, M. Scot Roberts, Kent R. Van Kampen, Prachi Sangle
-
Patent number: 11382968Abstract: Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.Type: GrantFiled: June 9, 2021Date of Patent: July 12, 2022Assignee: Altimmune Inc.Inventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
-
Publication number: 20220072121Abstract: CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.Type: ApplicationFiled: June 9, 2021Publication date: March 10, 2022Applicant: Altimmune, IncInventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
-
Patent number: 11141477Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: GrantFiled: March 28, 2021Date of Patent: October 12, 2021Assignee: Altimmune Inc.Inventor: De-chu C Tang
-
Publication number: 20210260181Abstract: Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.Type: ApplicationFiled: February 12, 2021Publication date: August 26, 2021Applicant: Altimmune, IncInventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
-
Publication number: 20210260183Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: ApplicationFiled: March 28, 2021Publication date: August 26, 2021Applicant: Altimmune, IncInventor: De-chu C Tang
-
Publication number: 20210260180Abstract: Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.Type: ApplicationFiled: February 12, 2021Publication date: August 26, 2021Applicant: Altimmune, IncInventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
-
Patent number: 11040099Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: GrantFiled: July 11, 2020Date of Patent: June 22, 2021Assignee: Altimmune, Inc.Inventor: De-Chu C Tang
-
Patent number: 11040100Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: GrantFiled: July 12, 2020Date of Patent: June 22, 2021Assignee: Altimmune Inc.Inventor: De-Chu C Tang
-
Publication number: 20200338183Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: ApplicationFiled: July 11, 2020Publication date: October 29, 2020Applicant: Altimmune, IncInventor: De-Chu C Tang
-
Publication number: 20200338188Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.Type: ApplicationFiled: July 10, 2020Publication date: October 29, 2020Applicants: Altimmune, Inc., Auburn UniversityInventors: De-Chu C Tang, Kent VAN KAMPEN, Haroldo Toro
-
Publication number: 20200338184Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: ApplicationFiled: July 12, 2020Publication date: October 29, 2020Applicant: Altimmune, IncInventor: De-Chu C Tang
-
Publication number: 20200316188Abstract: Provided herein are monovalent pharmaceutical compositions (vaccine compositions) and methods for inducing a multi-arm (mucosal, humoral and cell-mediated) immune response and extended seroprotection of at least 12 months post vaccination against influenza virus.Type: ApplicationFiled: April 6, 2020Publication date: October 8, 2020Applicant: Altimmune, IncInventors: Scot Roberts, Sybil Tasker
-
Patent number: 10744195Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.Type: GrantFiled: November 28, 2017Date of Patent: August 18, 2020Assignees: Altimmune Inc., Auburn UniversityInventors: De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro
-
Publication number: 20190134178Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: ApplicationFiled: November 30, 2018Publication date: May 9, 2019Applicant: Altimmune Inc.Inventor: De-chu C. TANG
-
Patent number: 10183069Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: GrantFiled: September 23, 2015Date of Patent: January 22, 2019Assignee: Altimmune Inc.Inventor: De-Chu C. Tang
-
Patent number: 9968667Abstract: The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.Type: GrantFiled: September 30, 2015Date of Patent: May 15, 2018Assignee: Altimmune Inc.Inventors: Chun-Ming Huang, JianFeng Zhang, De-Chu Tang
-
Patent number: 9855328Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.Type: GrantFiled: September 6, 2013Date of Patent: January 2, 2018Assignees: AUBURN UNIVERSITY, ALTIMMUNE INC.Inventors: De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro